| abstract |
The invention encompasses methods of treatment of interferon gamma (IFN-gamma)-mediated diseases using IFN-gamma inhibitors, such as anti-huIFN-gamma antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-gamma inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-gammaantibody. |